Figure 1
VD3-treated MR-DCs represent prototypic immunosuppressive DCs in vitro. Bone marrow–derived MR-DCs generated in vitro in the presence of VD3, or not (control-DCs), were challenged for 48 hours with a DC1-maturation cocktail (DC1c). (A) FACS analysis of the surface phenotype of control- and MR-DCs, with or without 48-hour stimulation with DC1c. (B) Detection by ELISA of IL-12p70 in culture supernatants of control- and MR-DCs after 48-hour stimulation with (or without) DC1c (mean ± SD shown). (C) Assessment by 3-day MLCs of the T-cell allostimulatory ability of control- and MR-DCs, untreated or after 48-hour stimulation with DC1c. (A-C) Representative data from 2 or more independent experiments. ND indicates not detected. *P < .05. ***P < .001.

VD3-treated MR-DCs represent prototypic immunosuppressive DCs in vitro. Bone marrow–derived MR-DCs generated in vitro in the presence of VD3, or not (control-DCs), were challenged for 48 hours with a DC1-maturation cocktail (DC1c). (A) FACS analysis of the surface phenotype of control- and MR-DCs, with or without 48-hour stimulation with DC1c. (B) Detection by ELISA of IL-12p70 in culture supernatants of control- and MR-DCs after 48-hour stimulation with (or without) DC1c (mean ± SD shown). (C) Assessment by 3-day MLCs of the T-cell allostimulatory ability of control- and MR-DCs, untreated or after 48-hour stimulation with DC1c. (A-C) Representative data from 2 or more independent experiments. ND indicates not detected. *P < .05. ***P < .001.

Close Modal

or Create an Account

Close Modal
Close Modal